The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia
NCT ID: NCT01493622
Last Updated: 2011-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
78 participants
INTERVENTIONAL
2010-06-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
placebo
Subjects will be given with 200mg/day placebo(100mg,bid) and variable dose SGA. All drugs will be administered orally.
placebo
variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
minocycline
Subjects will be given with 200mg/day minocycline (100mg,bid)and variable dose SGA.All drugs will be administered orally.
minocycline
variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
minocycline
variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
placebo
variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* were currently diagnosed with DSM-IV schizophrenia
* were able to comprehend the cognition test
* patients or guardian signed informed consent,were able to comprehend the procedure and aims of the study,agreed to join the study
* patient's current antipsychotic medication regimen must be stable
* must be in a stable living arrangement
Exclusion Criteria
* had acute,unstable,significant,or untreated medical illness besides schizophrenia
* were pregnant or breast-feeding;
* had a DSM-IV diagnosis of substance abuse or dependency;
* had a tendency to suicide or Violence,self-harm;
* had taken immunosuppressive agents in the preceding 3 months before study entry;
* had influenza or fever in the preceding 2 weeks before study entry;
* had a DSM-IV diagnosis of emotional psychosis,Mental retardation,etc.
* has suicidal attempts or ideation or violent behavior within the last 12 months
* patient has mental retardation or severe organic brain syndromes
* treatment with Electroconvulsive Therapy (ECT) within 6 months prior to screening
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fang Liu
Mental Health Institute of the Second Xiangya Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhao J Ping
Role: PRINCIPAL_INVESTIGATOR
The Second Xiangya Hospital, Central South University,China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry, The First Affiliated Hospital of Kunming Medical College
Kunming, Yunnan, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010 Feb;71(2):138-49. doi: 10.4088/JCP.08m04666yel. Epub 2009 Nov 3.
Liu F, Zhang B, Xie L, Ruan Y, Xu X, Zeng Y, Messina L, Zhao J, Fan X. Changes in plasma levels of nitric oxide metabolites and negative symptoms after 16-week minocycline treatment in patients with schizophrenia. Schizophr Res. 2018 Sep;199:390-394. doi: 10.1016/j.schres.2018.03.003. Epub 2018 Mar 9.
Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, Xie L, Zhang L, Yang L, Yang S, Yang J, Ruan Y, Zeng Y, Xu X, Zhao J. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014 Mar;153(1-3):169-76. doi: 10.1016/j.schres.2014.01.011. Epub 2014 Feb 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010LL02
Identifier Type: OTHER
Identifier Source: secondary_id
CSU-2010-PSY
Identifier Type: -
Identifier Source: org_study_id